Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Exemestane

Criteria

Inclusion Criteria:

• Subjects with postmenopausal breast cancer (including ovariectomy etc.).

Exclusion Criteria:

• Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).